Adjunct to diet & exercise in adults w/ type 2 DM. Monotherapy or in combination w/ metformin as initial therapy in treatment in naive patients w/ inadequate glycemic control by diet & exercise; in patients w/ inadequate glycemic control w/ maximal tolerated dose of metformin alone. In combination w/ metformin & sulfonylurea in patients w/ inadequate glycemic control w/ the maximal tolerated dose of metformin & sulfonylurea dual therapy. In combination w/ insulin (w/ or w/o metformin) in patients w/ inadequate glycemic control w/ stable dose of insulin.
View Zemiglo overdosage for action to be taken in the event of an overdose.
Administration
May be taken with or without food.
Contraindications
History of serious hypersensitivity reactions ie, angioedema or anaphylaxis, to another dipeptidyl peptidase-4 (DPP-4) inhibitor. Type 1 diabetes or diabetic ketoacidosis.
Do not use in patient w/ history of hypersensitivity; w/ type 1 DM, diabetic ketoacidosis, severe infection or accident-related severe injury. Avoid use w/ alcohol beverage. Not recommended in patients w/ NYHA Class II-IV cardiac status. History of pancreatitis. Concomitant use w/ drugs known to cause hypoglycemia ie, sulfonylurea or insulin. Consider discontinuation of treatment in possible severe joint pain. Not recommended during pregnancy & lactation. Childn <18 yr.
Sign Out
